Antag Therapeutics, a biopharmaceutical company focused on the development of novel treatments for obesity, has raised €80 million in a Series A financing round.

The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of BroadviewVentures), and Export and Investment Fund of Denmark (EIFO). The funds will be used to support the clinical development of AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose Dependent Insulinotropic Polypeptide Receptor (GIPR), and will also support Antag’s pipeline of monthly injectable therapies.